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were very scarce. Patients were distributed across SOI categories as follows: 3.9% 
mild, 51.8% moderate, 26.4% major, 17.9% severe with LOS 5.61, 10.78, 19.43 and 
34.60 days respectively. Costs for drugs ranged from € 139.82 in SOI1, € 150.26 in SOI2, 
€ 349.51 in SOI3 and € 758.41 in SOI4. Data on clinical biology amounted to € 17.13 per 
patient; on average 15 types of lab tests were used. Costs for imaging also varied 
by severity and were € 876.58, € 866.29, € 930.07 and € 1,247.45 for increasing levels of 
SOI. In total 39 different imaging tests were used covering among others functional 
measurements, radiology, Rx, CT and MRI. Total costs amounted to € 3,653 , € 5,583 , 
€ 9,489 , € 16,660 respectively. Compared to the national average these costs are 5% 
lower, mainly due to underestimation of honoraria. ConClusions: In-hospital 
costs increase with stroke severity, with the most severe patients costing 4.5 times 
more than mild patients. Bottom-up costing approximated the top-down costs.
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objeCtives: Various published sources report an incidence of symptomatic deep 
venous thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip 
or knee replacement ranging between 0.3 and 2%. This study aimed at assessing the 
in-hospital incidence of DVT/PE after major orthopaedic surgery in Belgium and the 
impact of these complications on the length of stay and hospitalization costs using 
retrospective data. Methods: The incidence of DVT/PE, the average hospitalization 
cost and the average length of stay (LOS) among patients hospitalized for hip or knee 
replacement surgery were estimated using the longitudinal IMS Hospital Disease 
Database (year 2013), including data (diagnoses, procedures, costs) on 24% of Belgian 
hospital beds. Stays were searched based on ICD-9-CM codes corresponding to hip 
replacement (81.51-81.52-81.53) and knee replacement (81.54-81.55). Occurrence 
of DVT/PE was identified with ICD-9 codes 451.1-451.2-453.4. The impact of a DVT/ 
PE complication on LOS/ cost was assessed through Wilcoxon non-parametrical 
tests. Results: 7,160 stays with hip replacement and 6,223 stays with knee replacement 
were retrieved in the database. The number of stays with a DVT/PE episode was 
respectively equal to 22 and 43 within the two subgroups, resulting in an incidence 
of 0.31% in patients with hip replacement and 0.69% in patients with knee replace-
ment. LOS of patients with a DVT/PE episode was more than twice as high after both 
hip (35.8 vs. 13.59 days; p< 0.001) and knee (31.2 vs. 9.9 days; p< 0.001) replacement. 
Hospitalization costs were also more than doubled in case of DVT/PE complication 
(€ 25,557 vs. € 12,721 in hip replacement; € 24,953 vs. € 11,298 in knee replacement; 
p< 0.001 in both cases). ConClusions: The incidences of symptomatic DVT and 
PE reported in the literature could be confirmed based on this retrospective search. 
The occurrence of DVT/PE increases dramatically both LOS and hospitalization costs 
in patients undergoing hip or knee surgery.
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objeCtives: Stroke is the second leading cause of death globally and the survivors 
are faced with long-term disability. Stroke survivors are also under the risk of recur-
rent strokes causing a potential burden on health care systems. Therefore, cost of 
stroke studies are of special importance to healthcare policy makers in order to 
predict and take precautions for stroke in their health care system. The aim of this 
study was to determine the direct economic cost of stroke from the payer perspec-
tive in Turkey. Methods: A multi-dimensional approach was used to estimate the 
direct costs of stroke in Turkey. First a large dataset covering 5 years data for 2000 
emergency department stroke admissions from a university hospital was analyzed. 
The data set covered information on the severity of the disease, socioeconomic 
status of the patients and also the medical procedures applied during the hospital 
stay. Second, the actual invoices of the same patients hospitalized in 2014 were 
analyzed. Third, a form was designed to explore the treatment strategies, medical 
procedures and resource requirements of stroke outpatients and inpatients. The 
form was applied to an expert panel and the resources determined by the panel 
were priced by the Social Security Institution’s official price list. Results: According 
to the expert panel part of the study, annual outpatient and monitoring costs were 
1.807,58 TL and intensive care and inpatient costs were 5.636,52 TL. The total annual 
cost of stroke per patient was calculated as 7.444,11 TL in Turkey. ConClusions: 
The study showed that stroke treatment had a significant economic burden on the 
healthcare budget. Outpatient and monitoring costs constituted %24 of total costs 
whereas inpatient costs constituted %76 of total costs.
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objeCtives: Venous thromboembolism (VTE) is a common disorder, with about 1 
per 1,000 people per year in the general population.Approximately two-thirds of 
cases of VTE present as deep vein thrombosis (DVT), the formation of a thrombus 
in a deep vein, usually of the lower limbs. Around one third of VTE cases present as 
pulmonary embolism (PE), occurring when dislodged thrombi (from a DVT) travel 
to the lungs. PE can cause sudden death and those who survive an episode occa-
sionally require intensive care, with recovery taking several weeks or months. The 
episodes involving inpatient care and complications could lower substantially the 
burden of diabetes.
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objeCtives: Patients with chronic heart failure (HF) in controlled trials do not 
fully represent real population followed in clinical practice. We wanted to give real 
world picture of epidemiology and hospitalization caractheristics of patients with 
HF, by analyzing administrative database of nearly 2,500,000 subjects. Evaluation 
of healthcare related costs over 1 year follow-up was performed. Methods: Data 
come from ARNO database that includes in-habitants of 7 Local Health Authorities 
of the Italian National Health Service (NHS). Patients were selected when admis-
sion for HF occurred over period of 5 years ( January 1, 2008 to December 31 2012). 
To confirm diagnosis, all patients discharged alive should be prescribed typical 
treatment for HF. Clinical characteristics co-morbidities, treatment, need for re-
hospitalization and mortality occurring in the 1st year following discharge were 
analyzed. Total costs for NHS were calculated as hospitalizations, treatments 
and out-of-hospital speciality visits or examinations. Results: 54,059 patients 
(2.2%) were admitted for HF. The great majority was admitted in Internal Medicine/
Geriatric Departments (69.5%). Of 54,059 patients, 41,413 were discharged alive and 
prescribed HF treatments. Need for re-hospitalization occurred frequently: 56.6% 
of patients was admitted at least once in 1-year following discharge, cardiovas-
cular admissions accounted for just 51% of the total hospitalizations. All-cause 1 
year mortality was 18.9%. Patient with HF generate a cost per year to NHS 7,429€ 
(11,867€ if first admission included). Cost per year were as follows: new hospitali-
zations 76%, drug prescriptions 16%, visits/examinations 8%. ConClusions: Real 
world evidence in HF provides findings different from randomized clinical trials. 
Patients are older and more frequently females. Rate of use of treatments is not 
optimal. All-cause mortality remains high and re-hospitalizations are frequent. 
In nearly half cases, re-hospitalizations are due to non CV reasons, documenting 
relevant role of advanced age and co-morbidities. Costs for NHS are mainly driven 
by hospital costs.
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objeCtives: Atrial Fibrillation (AF) is the most common arrhythmia in Europe. AF 
increases the risk of death and cost of care, and is the second leading risk factor 
for stroke. The study objective was to estimate healthcare resource utilization 
(HCRU) and treatment costs of non-valvular AF (NVAF) patients with and without 
stroke. Methods: Retrospective cohort study of patients newly diagnosed with 
NVAF from January 2003 to December 2013. Patients were identified using medical 
diagnoses (ICD-9 codes) and treatment prescriptions (ATC codes) in the Badalona 
Serveis Assistencials database. HCRU included overall hospital admissions, out-
patient consultations, home-based care, laboratory tests, and pharmacological 
treatments. Differences in annualized total cost rates (95% CIs) per patient were 
calculated in € (2014 tariffs) by estimating HCRU in propensity-score matched 
cohorts of NVAF patients with and without stroke. Results: Overall, 3,052 
patients with NVAF were identified in the study period, and 11.2% had at least one 
stroke event after NVAF diagnosis. Median follow-up time of patients with stroke 
was 519 days. In the first year after stroke, there was on average an incremental 
0.9 hospital admissions per patient, 0.9 additional ER admissions, 2.9 additional 
hospital outpatient consultations, 5.7 additional consultations at other sites, 4.2 
additional procedures/laboratory tests, and 265 additional DDDs of anticoagulant. 
The incremental total cost of stroke per patient was 12,085€ (12,069-12,101) in the 
first year, and 6,384€ (6,377-6,391) for the entire follow-up period. Total cost of 
stroke per patient was 4.4 times higher than non-stroke patients during the first 
year after stroke, and 2.9 times higher for the entire follow-up. ConClusions: 
In Spain, NVAF patients with stroke consumed additional HCRU and treatment 
costs compared to patients without stroke. The burden of stroke was particularly 
important in the first year after stroke, and hospitalizations were the main drivers 
of the increased HCRU and costs.
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objeCtives: To investigate the resources used by ischemic stroke patients when 
hospitalized, and examine this relationship by stroke severity. Comparing a bot-
tom-up costing approach with national top-down costs. Methods: Data from five 
Belgian hospitals were requested for the years 2008 up to 2011 detailing the length-
of-stay (LOS), drugs, medical imaging and clinical biology tests. Participating hospi-
tals were distributed across the country and included regional as well as teaching 
hospitals. Severity of the stroke was defined as mild, moderate, major or severe 
according to the Severity-of-Illness (SOI) categorization within APR-DRG category 
045, which is determined by the classification of primary and secondary diagnoses. 
Average bottom-up costs were compared to the national reimbursement received 
by hospitals. Results: 2,496 hospital admissions were included in our analysis; all 
admissions contributed to the LOS calculations, 2,364 observations were available 
for medical imaging, 1,954 for drug treatments whereas data for clinical biology 
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Discharge Abstract Database and National Ambulatory Care Reporting System 
database. All acute care hospitalization discharge abstracts with either conges-
tive heart failure (ICD-10 code I50.0) recorded as the most responsible diagnosis 
(MRDx) or contributing diagnosis amongst patients aged ≥ 18 were included in the 
study. Abstracts with a CHF MRDx were categorized in the CHF group. The remain-
ing abstracts were categorized into either the cardiovascular group (circulatory 
system disease MRDx (ICD-10 I00 – I99), excluding CHF) or non-cardiovascular 
group (non-circulatory system disease MRDx). Discharge abstracts with missing 
demographics, or absent without leave or against medical advice discharge sta-
tus were excluded. Results: 156,847; 66,056; and 127,847 CHF, cardiovascular, 
and non-cardiovascular group discharge abstracts were included, respectively, 
of which 10%, 13% and 21% of the respective group abstracts resulted in death. 
The national mean hospitalization visit cost was $10,123; $20,890; and $21,283 
for the CHF, cardiovascular, and non-cardiovascular groups respectively. For each 
CHF, cardiovascular, and non-cardiovascular group, a survival outcome incurred 
a lower national mean hospitalization visit cost at $9,222; $19,899; and $19,036 
whereas a death outcome incurred a high national mean hospitalization visit cost 
at $18,087; $27,642; and $29,887, respectively. ConClusions: Cardiovascular and 
non-cardiovascular hospitalizations result in higher mean hospitalization costs 
than those with a CHF MRDx. An opportunity exists for interventions reducing 
the number of any CHF related hospitalization to ease the burden on healthcare.
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objeCtives: Randomized clinical trials comparing percutaneous coronary inter-
ventions (PCI) and non-invasive treatment of acute coronary syndromes mostly 
favour the invasive approach. This study aimed at assessing whether in a real 
life setting PCI has an impact on outcomes as hospitalization cost, length of 
stay (LOS) and mortality in patients hospitalized for acute coronary syndromes 
(ACS) in Belgium. Methods: The hospitalization cost, average length of stay 
(LOS) and mortality among hospitalized patients with ACS were estimated using 
the longitudinal IMS Hospital Disease Database (year 2013), including data on 
about 24% of Belgian hospital beds. Stays were identified based on ICD-9 cod-
ing and split in ST-elevated Myocardial infarction (STEMI ICD-9: 410 excluding 
410.7), non-STEMI (NSTEMI: ICD-9: 410.7-411.89) and unstable angina (UA; ICD-9: 
411.1-411.8-413.0). PCIs were identified with ICD-9 code 36.0. Comparisons were 
performed using a Wilcoxon non-parametrical test for cost/ LOS and a Chi-square 
for mortality. Results: 2,528 STEMI, 2,815 NSTEMI and 407 UA hospitalizations 
were retrieved from the database, with respectively 1,457, 1,194 and 30 of them 
treated invasively. PCI resulted in higher costs in STEMI (€ 9,342 vs. € 8,165; p< 0.001) 
and UA (€ 9,186 vs. € 4,714; p< 0.001) and in lower costs in NSTEMI (€ 8,483 vs. € 9,483; 
p< 0.001). LOS of patients undergoing PCI was significantly lower in STEMI (6.2 
vs. 9.7 days; p< 0.001) and NSTEMI (5.6 vs. 10.9; p< 0.001). In-hospital mortality in 
patients with PCI was lower in both STEMI (6.2% vs. 21.4%; p< 0.001) and NSTEMI 
(1.6% vs. 8.0%; p< 0.001). LOS (5.5 vs. 5.9 days) and mortality (0.0% vs. 3.2%) were 
not significantly different in UA. ConClusions: Although information on the 
baseline characteristics of the different patients is limited, the findings of this 
retrospective study seem to support randomized clinical trials. Treatment with PCI 
significantly decreases the LOS and the mortality in patients with a myocardial 
infarction, at a limited marginal cost.
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objeCtives: To evaluate the costs and benefits of Yindanxintai dropping pills 
(Guizhou Junzhitang Pharmaceutical Company) for angina pectoris caused 
by coronary heart disease from the societal perspective. Methods: The com-
parator was chosen from published literature. Treatment results and costs were 
derived from published literature and government websites. A contingent valu-
ation survey was used to elicit the respondents’ willingness-to-pay (WTP) for 
angina pectoris treatments. The WTP was modeled as a function of the treat-
ment outcomes, design of questionnaire scenarios, individual health states and 
characteristics. A total of 351 questionnaires were completed. The primary out-
come was the annual net cost-benefit or incremental net cost-benefit per person 
tested. Results: WTP increased with the growth of effective rate. The average 
WTP was given 377 RMB per month (range 100 RMB to 2000 RMB) to the treatment 
with a 95% effective rate. There were 7 papers that provided adequate information 
to the further cost-benefit analysis (CBA). Results from the CBA indicated that 
Yindanxintai dropping pills had a positive annual net benefit when used alone, 
and the treatment with 56 days was superior to 28 days with an annual incre-
mental net benefit (AINB) of 4529 RMB per person tested. Yindanxintai dropping 
pills used with nitroglycerin tablets (Shanghai Sina Pharmaceutical Company) 
had greater net benefit than simvastatin tablets (Yangtze River Pharmaceutical 
Group) with nitroglycerin tablets (AINB= 1471 RMB). Yindanxintai dropping pills 
used with isosorbide mononitrate sustained release tablets (AstraZeneca AB), 
Xinkang tablets (Lunan Pharmaceutical Company), or Xinkang tablets and Xinke 
tablets (Guangzhou Nanxin Pharmaceutical Company) also had greater net ben-
efit than the other drugs used alone (AINB were 306 RMB, 479 RMB, 1067 RMB, 
respectively). The results of this research were proved robust through sensitivity 
analyses. ConClusions: Yindanxintai dropping pills is cost-beneficial in the 
treatment of angina pectoris caused by coronary heart disease either used alone 
or used with other drugs.
clinical course of DVT may also be complicated by recurrent episodes of DVT, the 
development of post-thrombotic syndrome (PTS), as well as chronic thromboem-
bolic pulmonary hypertension (CTEPH). The aim of study was to estimate the cost 
of VTE treatment in Turkey. Methods: The study was undertaken from the Turkish 
health care payer perspective. (SSI). An Excel sheet was formed to determine the 
healthcare resources used in treatment of VTE. VTE treatment costs were divided 
by anticoagulant use, monitoring INR, recurrent DVT, recurrent PE, non IC major 
bleeding (GIS), Intracranial bleed, CTEPH and PTS long term costs.Resource utiliza-
tion data were obtained via expert clinical views and included diagnosis costs and 
treatment costs. Unit costs were taken from the Social Security Institution’s Health 
Implementation Guideline. Results: According to the results of the study,cost 
ofanticoagulans were146,59 TL, monitoring INR costs were 90,00 TL, recurrent DVT 
costs were 1.972,41 TL, recurrent PE costs were 830,49 TL, non IC major bleeding 
(GIS) costs were 1.482,49, Intracranial bleed costs were 3.868,86 TL, CTEPH costs were 
22.228,12 TL and PTS long term costs were 754,29 TL in Turkey. ConClusions: The 
study showed that VTE treatment poses a high treatment cost due to recurrence 
and OAC complications in the Turkish health care system.
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objeCtives: Vietnam spends 6% of its GDP to health care. In context of insuf-
ficient evidence on quantifying the economic burden of cardiovascular disease in 
Vietnam, we conducted a study on the costs of Acute Myocardial Infarction (AMI). 
Costs were identified from the perspective of the health care payers, including 
health insurance providers and patients. Methods: Data was extracted from the 
database of a regional hospital in Vietnam. All patients with the single code I21 
according to the International Clarification of Disease 10 were included in the study. 
Costs were calculated in year 2013. Out-of-pockets payment was quantified as the 
net of health insurance (HI) reimbursement and actual payments. Results: 89 
patient-hospitalizations were included in the study, including 34 cases requiring 
percutaneous coronary intervention and 55 cases requiring medicine only. Mean 
costs of AMI were US$ 2,503 (+/-3,377) per hospitalization. Costs per hospitalization 
were higher in the group requiring percutaneous coronary intervention than in the 
group requiring medicine only at US$5,962 (+/- 3,197) and US$365 (+/- 401), respec-
tively. Out-of-pocket payments were approximately 60% of these costs. Generally, 
cost of AMI per hospitalization in Vietnam was higher than GDP per capita (US$ 
1,900). ConClusions: Our results indicate that MI prevention is needed to reduce 
the burden of disease as well as to avoid catastrophic expenditure and impoverish-
ment problemsin Vietnam. Our results also comprise essential building blocks for 
important variables in a future cost-effectiveness modeling exercise on cardiovas-
cular prevention.
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objeCtives: to compare the total treatment duration cost per patient between the 
two most used low-molecular-weight heparins (LMWHs) in Spain for the prophy-
laxis of the venous thromboembolism disease (VTE) and the treatment of deep 
vein thrombosis (DVT) with and without pulmonary embolism (EP), during the 
acute phase and at long term. Methods: patients in prophylaxis were classified 
as moderate or high according to the risk of the surgery. Patients with high risk 
were further classified by surgery type: 1) orthopedic or oncologic surgery, 2) other 
surgeries, and 3) medical patients (surgery is not performed by a surgical speciality 
but other specialists). Patients with DVT were divided into 10 kilogramme weight 
ranges as well as considering the distribution of the Spanish population in each 
range taken from the RIETE registry. Treatment duration was obtained from clini-
cal guidelines. Treatment duration and patient profile defined the strength and 
package size used to estimate the cost per patient in prophylaxis. Concerning 
DVT, only the most appropriate strengths for each weight range were considered. 
Costs are expressed in € of 2015 and calculated based on the retail price plus the 
value-added tax of each LMWH discounting the corresponding deduction accord-
ing to Royal Decrees. Results: administering enoxaparine instead of bemiparine 
represents a saving of 6€ (5%), 7€ (16%) and 7€ (16%) per patient per total treatment 
duration with high risk undergoing surgery type 1, 2 and 3, respectively, and 4€ 
(16%) per patient per total treatment duration with moderate risk. Average sav-
ings per patient per total treatment duration with DVT came to 61€ (56%) and 
354€ (46%) in the acute phase and at long term, respectively. ConClusions: the 
cost of treating VTE or DVT is lower when administering enoxaparine instead of 
bemiparine. Therefore, the use of enoxaparine represents an economic benefit 
for the Spanish health system.
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objeCtives: Chronic heart failure (CHF) affects more than 600,000 Canadians, 
resulting in thousands of hospitalizations and deaths each year. This study’s objec-
tive is to compare the mean cost ($CAD) of a CHF, cardiovascular, and non-cardi-
ovascular diagnosed hospitalization amongst acute care treated CHF diagnosed 
patients. This study builds upon previously presented Canadian CHF hospitaliza-
tion costing research. Methods: Hospital discharge abstracts recorded between 
2009 and 2013 were extracted from the Canadian Institute for Health Information’s 
